Tag Archives: IP

Innovation Act Passed By House

House

The Innovation Act (H.R. 3309), which is intended to reduce frivolous patent-related litigation, was passed by the House today. As we’ve noted, BIO does not support the bill in its current form, which would ultimately undermine biotech research and innovation by making it more difficult for patent holders with legitimate claims to protect their intellectual property. A number of Representatives offered amendments to the bill, several of which BIO supported. These amendments address serious shortcomings with the bill, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Innovation Act Threatens Biotech Innovation

AB23475

BIO has grave concerns regarding the Innovation Act (H.R. 3309), as reported by the House Judiciary Committee. The Innovation Act was introduced with the goal of furthering patent system reform, particularly with respect to patent-related litigation. We support increased transparency and oppose abusive litigation tactics. However, provisions in the Act remain overly broad in important respects and, if ultimately enacted, would continue to result in too many unintended and unknowable consequences for innovators who rely on the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

TRIPs Has Delivered: Patent Agreement Increases Drug Development

US Patent Application

The TRIPs (Trade Related Aspects of Intellectual Property) Agreement, effective in 1996, has resulted in multiple benefits for public health. The last blog post reviewed Progressive Economy’s finding of TRIPS at 20. One additional benefit not mentioned in the article is the explosion of molecules in clinical development. The World Intellectual Property Indicators – 2012 Edition reveals an overall growth in patent applications around the world. The report finds that patent applications “worldwide doubled from Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Patents Improve Public Health: Progressive Economy Reviews TRIPS at 20 Years

flags with blue sky

Progressive Economy released a research paper examining the effect of TRIPS (Trade-Related Aspects of Intellectual Property) on global health. Here are their findings quoted from their press release: “1. Since the TRIPS agreement went into effect on New Year’s Day 1995, research and development spending has risen significantly worldwide (relative to the size of GDP). For OECD members, the rise is from 2.1 percent to 2.4 percent of GDP, or in practice an additional $220 Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Neglected Diseases: What if IP was the Cure?

Biopharmaceuticals and Accountable Care Organizations: Balancing Cost and Quality

The Lancet Global Health Journal recently published an article “The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment” discussing the current research and development ongoing in this area.  They found 1,500 clinical trials were registered for neglected diseases which represents only 1% of all registered clinical trial activity.  Of the 123 new products in development for neglected disease, more than half were vaccines or biological products.  However, the article points out that Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , ,